Join
Live feed
·
INSIDERFilingvia Quantisnow
Stoke Therapeutics Inc. logo

Director Kaye Edward M. Md sold $221,154 worth of shares (12,126 units at $18.24), decreasing direct ownership by 7% to 153,470 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track STOK (Stoke Therapeutics Inc.) and more on Quantisnow.